ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Hematologic Cancer
Lymphoma
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Toronto, ON, CAN:

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE)

A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously ...

Not yet enrolling
Refractory Multiple Myeloma
Drug: Elranatamab injection

Phase 2

Ontario Clinical Oncology Group (OCOG)

Hamilton, Ontario, Canada and 4 other locations

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Toronto, Ontario, Canada and 145 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Isatuximab
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Toronto, Ontario, Canada and 48 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Toronto, Ontario, Canada and 59 other locations

phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma...

Enrolling
Multiple Myeloma
Drug: Selinexor
Drug: Mezigdomide

Phase 1, Phase 2

Karyopharm Therapeutics
Karyopharm Therapeutics

Toronto, Ontario, Canada and 24 other locations

1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: zevor-cel

Phase 1, Phase 2

CARsgen Therapeutics

Toronto, Ontario, Canada and 12 other locations

is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: CTX120

Phase 1

CRISPR Therapeutics
CRISPR Therapeutics

Toronto, Ontario, Canada and 9 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Toronto, Canada and 126 other locations

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone ma...

Enrolling
Multiple Myeloma
Drug: ABBV-383

Phase 1

TeneoOne

Hamilton, Ontario, Canada and 37 other locations

as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts:...

Active, not recruiting
Multiple Myeloma
Drug: CC-92328

Phase 1

Celgene
Celgene

Toronto, Ontario, Canada and 14 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems